Cargando…
Pharmacokinetic, pharmacodynamic, and transcriptomic analysis of chronic levetiracetam treatment in 5XFAD mice: A MODEL‐AD preclinical testing core study
INTRODUCTION: Hyperexcitability and epileptiform activity are commonplace in Alzheimer's disease (AD) patients and associated with impaired cognitive function. The anti‐seizure drug levetiracetam (LEV) is currently being evaluated in clinical trials for ability to reduce epileptiform activity a...
Autores principales: | Onos, Kristen D., Quinney, Sara K., Jones, David R., Masters, Andrea R., Pandey, Ravi, Keezer, Kelly J., Biesdorf, Carla, Metzger, Ingrid F., Meyers, Jill A., Peters, Johnathon, Persohn, Scott C., McCarthy, Brian P., Bedwell, Amanda A., Figueiredo, Lucas L., Cope, Zackary A., Sasner, Michael, Howell, Gareth R., Williams, Harriet M., Oblak, Adrian L., Lamb, Bruce T., Carter, Gregory W., Rizzo, Stacey J. Sukoff, Territo, Paul R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398229/ https://www.ncbi.nlm.nih.gov/pubmed/36016830 http://dx.doi.org/10.1002/trc2.12329 |
Ejemplares similares
-
Prophylactic evaluation of verubecestat on disease‐ and symptom‐modifying effects in 5XFAD mice
por: Oblak, Adrian L., et al.
Publicado: (2022) -
Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD Study
por: Oblak, Adrian L., et al.
Publicado: (2021) -
Cortical cerebrovascular and metabolic perturbations in the 5xFAD mouse model of Alzheimer’s disease
por: Jullienne, Amandine, et al.
Publicado: (2023) -
Plcg2(M28L) Interacts With High Fat/High Sugar Diet to Accelerate Alzheimer’s Disease-Relevant Phenotypes in Mice
por: Oblak, Adrian L., et al.
Publicado: (2022) -
Uncovering Disease Mechanisms in a Novel Mouse Model Expressing Humanized APOEε4 and Trem2*R47H
por: Kotredes, Kevin P., et al.
Publicado: (2021)